Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Utilizing Interventional Radiology and Liver-directed Therapies

February 26th 2024

Mechanism of action for liver-directed therapies in HCC are illustrated by Anne Covey, MD, an interventional radiologist.

Hepatocellular Carcinoma (HCC) Disease State Overview

February 26th 2024

Anthony El-Khoueiry, MD, opens the discussion by defining the current prevalence of hepatocellular carcinoma (HCC).

Further Validation Required If AI Models Are to Revolutionize GI Cancer Care

February 26th 2024

Jacob Shreve, MD, MS, highlights the intersection between artificial intelligence and personalized medicine, as well as its potential utility in gastrointestinal cancers.

Dr Kim on the Addition of NALIRIFOX to the Pancreatic Cancer Treatment Paradigm

February 22nd 2024

Dae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.

Dr Overman on the Potential Use of Endoscopy and ctNDA in Nonoperative GI Cancer Management

February 21st 2024

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA to guide nonoperative management approaches in gastrointestinal cancers.

Bridging the Gap: Geriatric Assessment vs Routine Provider Evaluation in Gastroesophageal Cancer Care

February 21st 2024

Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.

FDA Grants Fast Track Status to IMM-1-104 for Pancreatic Cancer

February 21st 2024

IMM-1-104 received FDA fast track designation for use in patients with pancreatic ductal adenocarcinoma who have progressed on 1 line of treatment.

Dr Bryant on the Influence of Germline DNA Repair Mutations on Therapeutic Development in PDAC

February 20th 2024

John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

Dr Shreve on the Potential Impact and Utility of AI in Cancer Care

February 16th 2024

Jacob Shreve, MD, discusses the potential impact of implementing artificial intelligence into cancer care.

Dr Dotan on the Use of Geriatric Assessments to Identify Unique Challenges in GI Cancer

February 15th 2024

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

February 14th 2024

Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.

FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

February 14th 2024

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Dr Wainberg on the FDA Approval of NALIRIFOX in mPDAC

February 13th 2024

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

FDA Approves Frontline NALIRIFOX for Metastatic Pancreatic Adenocarcinoma

February 13th 2024

The FDA has approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin, for the frontline treatment of metastatic pancreatic adenocarcinoma.

FDA Grants Breakthrough Therapy Designation to AlphaMedix for Gastroenteropancreatic Neuroendocrine Tumors

February 12th 2024

AlphaMedix has received breakthrough therapy designation from the FDA for use in select patients with gastroenteropancreatic neuroendocrine tumors.

Navigating FGFRi Therapy Adverse Effects: Nail Toxicities

February 7th 2024

Experts share preventative and management strategies for nail toxicities and mouth sores that can cause significant quality of life issues for patients being treated with FGFRi.

Monitoring and Managing Hyperphosphatemia

February 7th 2024

Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE.

Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma

February 6th 2024

Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.

FDA Grants Orphan Drug Designation to Efineptakin Alfa for Pancreatic Cancer

February 2nd 2024

Efineptakin alfa received an orphan drug designation from the FDA for use as a potential therapeutic option in patients with pancreatic cancer.

Dr Bryant on the Background For Investigating Germline DNA Repair Mutations in PDAC

February 2nd 2024

John Michael Bryant, MD, discusses the effects of germline DNA repair mutations on radiosensitivity in patients with pancreatic ductal adenocarcinoma.